anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Thin-cap fibro atheroma (TCFA) was defined as a lipid-rich plaque with the thinnest fibrous cap thickness\<65um. Plaque rupture was identified by the presence of fibrous cap discontinuity with a clear cavity formation inside the plaque. Plaque erosion is characterized by luminal thrombus and absence of the endothelium or without evidence of fibrous cap disruption. Fibro calcific plaque contains OCT evidence of fibrous tissue along with calcium that appears as a signal-poor or heterogeneous region with a sharply delineated border which is applied to larger calcifications. Calcified nodule is characterized as a signal or multiple regions of calcium protruding into the lumen, superficial calcification accompanied by substantive calcium proximal and or distal to the lesion. Thrombus is defined as a mass attached to luminal surface or floating within the lumen. It is seen as a protrusion inside the lumen of the artery with signal attenuation.
PURPOSE:To obtain a pack material capable of suitably adsorbing and removing fouling, etc., on the skin surface and simultaneously effectively carrying out sterilization of the skin, etc., by mixing HINOKI (white cedar) powder in other ingredients. CONSTITUTION:A beautifying pack material obtained by mixing powder of woody and leaf parts of HINOKI in a beautifying pack material in the form of jelly, paste or powder. In the case of the jelly form, a paste, such pregelatinized starch or PVA, or a humectant, such as glycerol, is dissolved in water or an aqueous solution of an alcohol and the powder of HINOKI is homogeneously dispersed in the solution. In the case of the pasty form, the powder of the HINOKI is dispersed in an oil, such as olive oil, and, a humectant, as necessary, is added. Phytontids which are aromatic substances of the HINOKI have action of tranquilizing excitation of nerves and sterilizing and users are enveloped in aroma during use. The material can be pleasantly usable and effects on various dermatophathies are expected.
The pharmacist prepared hydrocortisone and normal saline solution 100 ml starts dose at least 200 mg/day according to doctor's order after patient meets the criteria of refractory septic shock then continues conventional cessation of hydrocortisone according to doctor's order after required dose of vasopressor less than 0.1 mcg/kg/min. The nurse serially records capillary blood glucose and serum sodium following the doctor's order.
<P>PROBLEM TO BE SOLVED: To provide an epidermal keratinization normalizing agent which activates epidermal keratinizing cells, has an action to promote the expression of involucrin and keratin 10 of the constituting proteins of cornified envelope, and excels in safety.  <P>SOLUTION: The epidermal keratinization normalizing agent comprises an acidic xylooligosaccharide as an active ingredient. The acidic xylooligosaccharide has at least one uronic acid residue in the molecule as a side chain. The uronic acid is glucuronic acid or 4-O-methyl-glucuronic acid. The acidic xylooligosaccharide is obtained by "enzymatically and/or physicochemically treating a lignocellulose material to obtain a complex of a xylooligosaccharide component and a lignin component and then subjecting the complex to acid hydrolysis treatment to obtain a xylooligosaccharide mixture".  <P>COPYRIGHT: (C)2009,JPO&INPIT
A composition for administration to a subject is disclosed. The composition comprises at least one botanical active component. The botanical active component is present in the composition in an amount effective to inhibit advanced glycation end products (AGEs) in skin of the subject. The botanical active component comprises at least one extract selected from the group consisting of: i) an extract of  Dendrobium officinale  flower; ii) an extract of  Scrophularia ningpoensis ; iii) an extract of  Eucommia ulmoides ; and iv) combinations of i) to iii). The composition may be in the form of a topical composition, e.g., for topical application. The composition may also be in the form of an oral composition, e.g., for ingestion. A method of inhibiting advanced glycation end products (AGEs) in skin of a subject is also provided. The method comprises administering an effective amount of the composition to the subject.
Manganese (Mn) is an essential micronutrient required for various biological processes but excess exposure to Mn can cause neurotoxicity. However, there are few reports regarding the toxicity effect of Mn on the kidney as well as the underlying molecule mechanism. Herein, in vivo experiments were adopted to assess the toxicity effects associated with Mn, and found that chronic Mn treatment induced the injury of glomerular podocytes but not renal tubule in rats. Genome-wide CRISPR/Cas9 knockout screen was then employed to explore the biotargets of the toxic effect of Mn on podocytes. Through functional analyses of the enriched candidate genes, NLRP10 was found to be significantly up-regulated and mediated Mn-induced podocyte apoptosis. Further mechanism investigation revealed that NLRP10 expression was regulated by demethylase AlkB homolog 5 (ALKBH5) in an m6A-dependent fashion upon Mn treatment. Moreover, Mn could directly bind to Metadherin (MTDH) and promoted its combination with ALKBH5 to promote NLRP10 expression and cell apoptosis. Finally, logistic regressions, restricted cubic spline regressions and uniform cubic B-spline were used to investigate the association between Mn exposure and the risk of chronic kidney disease (CKD). A U-shaped nonlinear relationship between CKD risk and plasma Mn level, and a positive linear relationship between CKD risk and urinary Mn levels was found in our case-control study. To sum up, our findings illustrated that m6A-dependent NLRP10 regulation is indispensable for podocyte apoptosis and nephrotoxicity induced by Mn, providing fresh insight into understanding the health risk of Mn and a novel target for preventing renal injury in Mn-intoxicated patients.
Only persons trained in the administration of general anesthesia should administer SUPRANE. Only a vaporizer specifically designed and designated for use with desflurane should be utilized for its administration. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available.

SUPRANE is administered by inhalation. The administration of general anesthesia must be individualized based on the patient’s response. Hypotension and respiratory depression increase as anesthesia with SUPRANE is deepened. The minimum alveolar concentration (MAC) of SUPRANE decreases with increasing patient age. The MAC for SUPRANE is also reduced by concomitant N2O administration (see Table 1). The dose should be adjusted accordingly. The following table provides mean relative potency based upon age and effect of N2O in predominately ASA physical status I or II patients.

Benzodiazepines and opioids decrease the MAC of SUPRANE [See Drug Interactions (7.1, Table 3)]. SUPRANE also decreases the doses of neuromuscular blocking agents required [See Drug Interactions (7.2, Table 4)]. The dose should be adjusted accordingly.
Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of cycle 1, escalating to 27 mg/m² on days 8, 9, 15, and 16 of cycle 1 and continuing on days 1, 2, 8, 9, 15, and 16 of cycle 2 through cycle 12 and then from cycle 13 through cycle 18, 27 mg/m² on days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on days 1 to 21 from cycle 1 through cycle 18 and from cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22 from cycle 1 through cycle 18 and from cycle 19 and higher.
Adult Clinical Studies

A double-blind, placebo-controlled, multicenter US clinical trial involving obese patients with type 2 diabetes mellitus whose hyperglycemia was not adequately controlled with dietary management alone (baseline fasting plasma glucose [FPG] of approximately 240 mg/dL) was conducted. Patients were treated with Metformin Hydrochloride Tablets (up to 2550 mg/day) or placebo for 29 weeks. The results are presented in Table 7.

Mean baseline body weight was 201 lbs and 206 lbs in the Metformin Hydrochloride Tablets and placebo arms, respectively. Mean change in body weight from baseline to week 29 was -1.4 lbs and -2.4 lbs in the Metformin Hydrochloride Tablets and placebo arms, respectively. A 29-week, double-blind, placebo-controlled study of Metformin Hydrochloride Tablets and glyburide, alone and in combination, was conducted in obese patients with type 2 diabetes mellitus who had failed to achieve adequate glycemic control while on maximum doses of glyburide (baseline FPG of approximately 250 mg/dL). Patients randomized to the combination arm started therapy with Metformin Hydrochloride Tablets 500 mg and glyburide 20 mg. At the end of each week of the first 4 weeks of the trial, these patients had their dosages of Metformin Hydrochloride Tablets increased by 500 mg if they had failed to reach target fasting plasma glucose. After week 4, such dosage adjustments were made monthly, although no patient was allowed to exceed Metformin Hydrochloride Tablets 2500 mg. Patients in the Metformin Hydrochloride Tablets only arm (metformin plus placebo) discontinued glyburide and followed the same titration schedule. Patients in the glyburide arm continued the same dose of glyburide. At the end of the trial, approximately 70% of the patients in the combination group were taking Metformin Hydrochloride Tablets 2000 mg/glyburide 20 mg or Metformin Hydrochloride Tablets 2500 mg/glyburide 20 mg. The results are displayed in Table 8.

Mean baseline body weight was 202 lbs, 203 lbs, and 204 lbs in the Metformin/glyburide, glyburide, and Metformin arms, respectively. Mean change in body weight from baseline to week 29 was 0.9 lbs, -0.7 lbs, and -8.4 lbs in the Metformin/glyburide, glyburide, and Metformin arms, respectively.

Pediatric Clinical Studies

A double-blind, placebo-controlled study in pediatric patients aged 10 to 16 years with type 2 diabetes mellitus (mean FPG 182.2 mg/dL), treatment with Metformin Hydrochloride Tablets (up to 2000 mg/day) for up to 16 weeks (mean duration of treatment 11 weeks) was conducted. The results are displayed in Table 9.

Mean baseline body weight was 205 lbs and 189 lbs in the Metformin Hydrochloride Tablets and placebo arms, respectively. Mean change in body weight from baseline to week 16 was -3.3 lbs and -2.0 lbs in the Metformin Hydrochloride Tablets and placebo arms, respectively.
ABSTRACT OF THE DISCLOSURE      Integral, solid dosage forms containing active chemical compounds in a high moisture content macromolecular gel-lattice vehicle.  The gel-lattice matrix vehicle may contain various active chemical compounds in the form of aqueous solutions, aqueous colloidal suspensions, aqueous macro- and microcrystalline suspensions.  The gel-lattice matrix vehicle comprises from 4-50% water and sets to a relatively rigid, but not brittle, gel system upon cooling and drying to a final water content of 5-20%, typically 15-20%.  The gel-lattice matrix dosageform is sufficiently stable that no capsule covering or shell is required.  The gel-lattice dosage forms are extruded or die-formed in various shapes, and do not stick together in bulk.  The dosage forms may be used as carriers for various types of chemical compounds, including pharmaceuticals, medicinals, foods, and cosmetics.
MSK will contact all families of 1-year survivors of unilateral retinoblastoma treated with enucleation or intra-arterial chemotherapy at MSK and TCH between 2006 or later for completion of validated questionnaires integrating the BASC-3 and PROMIS surveys. The survey may be administered in-person during clinic or by mail, based upon participant preference.
Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
A fragrance composition is provided to reproduce a fragrance of rosa rugosa thunb. var. rugosa by containing a dimethyl octanol and a dimethyl octanyl acetate as a principal component of rosa rugosa thunb. var. rugosa such as geraniol, Nerol, cis-3-hexenyl acetate, citronellol and Phenethyl alcohol, to improve taste of the fragrance and to be used as a composition for skin external application. A fragrance composition reproducing the fragrance of rosa rugosa thunb. var. rugosa comprises a fragrance component of the rosa rugosa thunb. var. rugosa, a dimethyl octanol and a dimethyl octanyl acetate as an active ingredient. The fragrance component of the rosa rugosa thunb. var. rugosa is geraniol, Nerol, cis-3-hexenyl acetate, Citronellol and Phenethyl alcohol and additionally 3-Methyl-3-butenol, prenol, citral, Benzyl alcohol, geranyl acetate, citronellyl acetate, Cyclohexyl isothiocyanate, cis-3-Hexenol, 3-Methyl-3-butenal and neryl acetate.
Patients using this topical powder should receive the following information and instructions:

  1. The patient should be instructed to use this powder as directed (including the replacement of missed doses). This topical powder is not for any disorder other than that for which it is prescribed.
  2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.
  3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly.
This invention relates to the use of water-soluble zinc salts as anti-viral agents in genital lubricants (such as condom lubricants or stand-alone gels), to reduce the risk of infection by sexually transmitted viruses. Such zinc-containing anti-viral lubricants can be spread on the shaft of the penis or inside the vagina before sexual intercourse, or applied in other suitable manners that causes the lubricant fluid to be coated on one or more genital surfaces during intercourse. These lubricants also can be sealed in watertight packages containing lubricated condoms, or packaged and sold as "stand-alone" lubricants in watertight containers without condoms. Preferred lubricants contain a water-soluble lubricating agent, such as glycerin or polyethylene glycol, and a suitable zinc salt, and water, to promote ionization of the salt and release of zinc ions (Zn++). Such lubricants may also contain a thickening or suspending agent, such as a cellulose derivative, a natural gum compound, or a hydrophilic polymer, to provide a gel. Suitable zinc salts include water-soluble organic salts having relatively low molecular weights (including zinc acetate, butyrate, gluconate, glycerate, glycolate, lactate, propionate, etc.). Highly ionizing inorganic salts, such as zinc chloride or sulfate, can also be used in some formulations. Several preferred salts were tested by human volunteers, during intercourse, and did not cause any detectable irritation.
Controversial data have been reported on the prognostic value of C-X-C motif chemokine receptor 4 (CXCR4) in chronic lymphocytic leukemia (CLL). This prospective, single-center, observational study aimed to evaluate the role of CXCR4 in the pathophysiology of CLL and its prognostic role. A total of 158 patients of CLL were enrolled, and CXCR4 expression on CLL cells was detected by flow cytometry (FCM) at initial diagnosis. The patients were divided into 2 groups according to the CXCR4 mean fluorescence intensity (MFI) median. Also, four patient specimens from the CXCR4low and CXCR4high groups were selected for RNASeq analysis. The progression-free survival (PFS) of CLL patients in the CXCR4high group was significantly shorter than the CXCR4low group, with a median follow-up time of 27 months (log-rank P < 0.001). Moreover, CXCR4 overexpression (MFI > 3376) was an independent marker of poor PFS in CLL patients (P < 0.001). Analysis of RNASeq results revealed that CXCR4 plays an important role in the migration of CLL. Collectively, CXCR4 expression levels on leukemia cells can be detected rapidly by FCM. CXCR4 overexpression was significantly associated with poorer prognosis in CLL patients within a shorter follow-up time.
Migraine is a common headache disorder which leads to significantly impaired quality of life, absence from work, loss of productivity in workplace and reduced vitality in social functioning. A structured migraine diary can be a valuable aid for improving communication between patients and physicians regarding migraine disability and treatment outcomes. The other possible measure to ensure improved outcome in migraine patients is better adherence to prophylactic treatment of migraine. Migraine prophylaxis is by pills that have to be taken every day at fixed time to ensure best outcomes. However, it is known that patients with migraine often are not adherent to prophylactic medications. Regular pill reminders issued through smartphone based applications may help improve medication adherence and hence, headache outcomes. Though smartphone based migraine tracker digital applications are available, they mostly are aimed at capturing headache characteristics. The efficacy of providing pill reminders along with patient educational materials and community blog to enable migraineurs share their experiences with each other has not been studied in controlled trials. It is known that patients who are well informed about their chronic diseases such as migraine often have better outcomes. Busy clinicians often resort to providing pamphlets regarding the disease, triggers, acute pain relief medications, prophylactic therapy etc. However, it is yet to be studied if a digital application with all these inbuilt features, which are easily accessible at the finger tips would lead to better information uptake and improved compliance and self management. This RCT would try to assess this gap in knowledge.
INTRODUCTION: Heart transplantations are lifesaving for patients with end-stage heart failure. It is pertinent for the multidisciplinary care team to understand how heart transplant patients succumbed to death and the complications that occurred. In this study, we performed a comprehensive retrospective review of all the autopsies performed in our institute for heart transplant patients and report the trend of demographic data, cause of death, and autopsy findings.
MATERIALS AND METHODS: Reports, photos, and slides of autopsies performed at our institute from 1990 to 2023 for heart transplant patients were reviewed. Pertinent demographic data (age, gender, pretransplant diagnosis), clinical data (clinical history of rejection, complication, time interval from transplant to death, clinical cause of death) and pathological findings (allograft pathology, infectious etiology, other findings related to cause of death) were reviewed, documented, and analyzed.
RESULTS: We identified 88 cases, consisting of 53 male and 35 female patients. The median age at transplant was 26 years, while 28.5 years was the median age at death. The median interval from transplant to death was 10 months. The cases were classified in three categories based on length of survival post-transplant: Superacute (<1 month, 21%), Early (1 month-12 months, 30%), and Late (> 12 months, 49%). Slides were unavailable for review in 15 cases, which were excluded from cause of death (COD) evaluation. We categorized 41.1% of cases as allograft-related COD and 58.9% as non-allograft-related COD. Six of the CODs were not perceived premortem. These unexpected CODs included moderate/severe acute cellular rejection in a patient with a recently negative biopsy, dehiscent suture caused by a fungal abscess, an aorto-bronchial fistula, CMV myocarditis, acute abdominal bleeding, and ruptured atherosclerotic plaques with acute myocardial infarction.
CONCLUSION: We systematically reviewed 33 years of heart transplant autopsies. We found that 41.1% of deaths were allograft related, with infection being the most frequent COD. While the rate of unexpected findings was low, the findings demonstrate the continued utility of autopsy in patient evaluation.
Intestinal ischemia/reperfusion injury (IRI) poses a serious threat to human survival and quality of life with high mortality and morbidity rates. The current absence of effective treatments for intestinal IRI highlights the urgent need to identify new therapeutic targets. Ursolic acid (UA), a pentacyclic triterpene natural compound, has been shown to possess various pharmacological properties including intestinal protection. However, its potential protective efficacy on intestinal IRI remains elusive. This study aimed to investigate the effect of UA on intestinal IRI and explore the underlying mechanisms. To achieve this, we utilized network pharmacology to analyze the mechanism of UA in intestinal IRI and assessed UA's effects on intestinal IRI using a mouse model of superior mesenteric artery occlusion/reperfusion and an in vitro model of oxygen-glucose deprivation and reperfusion-induced IEC-6 cells. Our results demonstrated that UA improved necroptosis through the RIP1/RIP3/MLKL pathway, reduced necroinflammation via the HMGB1/TLR4/NF-κB pathway, attenuated morphological damage, and enhanced intestinal barrier function. Furthermore, UA pretreatment downregulated the phosphorylation level of signal transducer and activator of transcription 3 (STAT3). The effects of UA were attenuated by the STAT3 agonist Colivelin. In conclusion, our study suggests that UA can improve intestinal IRI by inhibiting necroptosis in enterocytes via the suppression of STAT3 activation. These results provide a theoretical basis for UA treatment of intestinal IRI and related clinical diseases.
The masking cream for skin care contains the egg yolk, lanolin, the structure-forming components, the oil phase, the active additives, the preserving agents, and water. The oil phase comprises the sunflower oil. The honey is used as the active additive. In addition, the cream contains Trilon B. The additional structure-forming components comprise salicylic acid and triethanolamine. Polyminerals comprising magnesium, zinc, iodine, potassium, calcium, copper, selenium, iron, gold, and silver constitute the active additives. The following substances are used as the filling agents: Naphtalan, Cholosas and the components of plant origin extracted from the sage, the carrot, the spinach, the champignon, the strawberry, the beet, and the cowberry.
The present invention discloses Chinese and western compound medicine for treating stomach disease, which belongs to the range of stomach medicine and is composed of the match of seventeen Chinese medicine such as lanceolata, atractylodes, tuckahoe, chicken's gizzard-membrane, milk vetch, liquorice, haw, medicated leaven, malt, etc., and a little amount of western medicine such as chloromycetin, oxytetracycline, furazolidone, etc. The present invention is mainly used for treating all kinds of acute stomach ulcer, chronic stomach ulcer, reflux gastritis and atrophic gastritis, and is also used for preventing stomach cancer. The Chinese and western compound medicine for treating stomach disease of the present invention has the functions of the Chinese medicine of dispelling cold, removing rheumatism, promoting blood circulation, regulating qi, tonifying and strengthening the spleen, and adjusting the spleen and the stomach and the western medicine of eliminating inflammation, killing pyloric spiral bacilli and treating symptoms and basic disease causes. The present invention has the characteristics of shortest therapeutic time, reliable therapeutic effect, low recurrence rate and rapid constitution recovery. The Chinese medicine and the western medicine are compounded for achieving the effect of treating the symptoms and the basic disease causes. The present invention can cure general stomach disease within one month to one year, and has the advantage of low medical cost which can be accepted by general wage earners and retirees.